Câncer de Mama 2013: Para onde vamos?

Transcrição

1 Câncer de Mama 2013: Para onde vamos? Objetivos do Simpósio Câncer de Mama - Gramado : Abordar as perguntas e as controvérsias mais críticas da atualidade. Oferecer oportunidade para uma interação ativa com especialistas nacionais e internacionais. Orientar o participante para as principais questões que estão sendo estudadas no momento e quais os estudos importantes que estão sendo conduzidos para respondê-las. Programa Científico Dia 29 de Agosto de QUINTA FEIRA 12h00-14h00 Inscrições e credenciamento 14h00-16h00 16h00-16h30 16h30-18h00 Tópicos de Radiologia/ Radiology Topics Moderadores: Ruffo de Freitas Junior (GO) e Alexandre Vicente Andrade (SP) DCIS: How to manage the possibility of overdiagnosis -Kelly Hunt (USA) A tomossíntese (mamografia 3D) é imprescindível na avaliação da mama? Sim /Yes- Aron Belfer (SP) Não/No Radiá Santos (RS) Exérese percutânea de lesões benignas de mama com sistema a vácuo Lúcio De Carli (RS) Preoperative MRI: should it be routine before conservative surgery? Sim/Yes - Fábio Torres (Colômbia) Não/No - Judy Boughey (USA) Mesa Redonda/Round Table : Manejo Cirúrgico da Axila / Surgical Management of the Axila Moderador: Antonio Frasson (RS) Can a complete axillary dissection be avoided in breast conservative surgery with more than 3 positive nodes? Kelly Hunt (USA) Can a complete axillary dissection be avoided when performing a mastectomy with positive sentinel node? Cesar Cabello dos Santos (SP) Should patients with positive lymphnodes submitted to neoadjuvant treatment be offered a complete axillary dissection? Judy Boughey (USA) 19h00 Coquetel Local: Área de Exposição 1

2 Espaço Érico Veríssimo sala E Special Parallel Session in Mama Gramado Targeted Therapy in Breast Cancer: Current Concepts with a Focus on Toxicity Diagnosis and Management of Special Toxicities Objectives: Most of the advances observed in the treatment of BC over the last 15 years have been seen with the introduction of Targeted Therapies. These agents, while demonstrating significant benefits in the management of specific subsets of BC patients are, by nature, different from the chemotherapeutic agents we have been utilizing for decades. While most oncologists are very well trained in identifying and managing standard chemotherapy related side effects, the use of some of the targeted agents that have reached the clinic has been associated with different toxicities that require different skills and special attention to be able to diagnose and manage these particular side effects. The main objective of this session is to present the most common particular toxicities associated with targeted therapies in current use for the treatment of BC with two main focuses: the ability of identifying them and discussing the best management for these conditions to allow an optimal delivery of these agents. At the conclusion of this session participants should be able to identify, diagnose and deliver appropriate management for the most common toxicities expected with the administration of the currently approved targeted agents for Breast Cancer patients. Note: This session requires specific advanced registration. A limited number of participants will be allowed, as space is limited. 02:30pm 02:35pm - Introduction and Presentation of educational objectives Carlos Barrios (RS) I. Particular Toxicities Associated with anti-her2 Therapy 02:35pm 02:50pm Special Toxicities for the combination of Trastuzumab and Pertuzumab Gustavo Ismael (SP) 02:50pm 03:05pm Special Toxicities Associated with Lapatinib Daniel Gimenes (SP) 03:05pm 03:20pm Toxicities Associated with TDM1 Therapy Marcelo Cruz (SP) 03:20pm 03:35pm Discussion II. Particular Toxicities Associated with mtor inhibition 03:35pm 03:50pm Cutaneous and Mucosal Toxicities Associated with Everolimus Max Mano (SP) 03:50pm 04:05pm Metabolic Complications of Everolimus - Ricardo Caponero (SP) 04:05pm 04:20pm Non-Infectious Pneumonitis: Diagnosis and Optimal Management- Antonio Buzaid (SP) 04:20pm - 04:35pm Discussion 04:35pm- 05:00pm Break III. Toxicities Associated with Anti-angiogenic Therapy in Breast Cancer 05:00pm 05:15pm Toxicity Associated with Bevacizumab Therapy - Antonio Dal Pizzol Jr (RS) 05:15pm 05:30pm Discussion IV. The Future: Toxicities Associated with Promising Drug Candidates for Breast Cancer 05:30pm 05:45pm Toxicities Associated with anti-cdk 4/6 Inhibition in HR positive BC Carlos Barrios (RS) 05:45pm 06:00pm Toxicities of PARP Inhibition Carlos Barrios (RS) 06:00pm 06:05pm Summary and Concluding Remarks - Carlos Barrios (RS) 07:00pm Cocktail 2

3 Dia 30 de agosto de SEXTA FEIRA 08h30-10h30 Pacientes com Doença Inicial Moderadores: Mastologista: Eduardo Millen (RJ) Oncologista: Carlos A. Sampaio (BA) Should the molecular profile interfere with the indication of the surgical procedure? Kelly Hunt (USA) Quando a mastectomia é necessária? Fabricio Brenelli (SP) Doença Luminal A/B (HER2 negativa): Quem se beneficia de quimioterapia e qual o melhor regime? Pedro Liedke (RS) Controvérsia - Decisões terapêuticas personalizadas além da IHQ : perfil molecular está indicado em todas as pacientes RH+ LN Moderador : Antônio Frasson (RS) Sim- Sérgio Simon (SP) Não- José Bines (RJ) 10h30-11h00 Intervalo 11h00-11h45 Conferência - Obesidade e Câncer de Mama: qual a evidência como fator de risco e prognóstico? Moderador: Carlos Barrios (RS) Conferencista: Daniel Tabak (RJ) 11h45 12h45 Mesa Redonda - Duração do Tratamento Adjuvante 2013/ Adjuvant Treatment Duration Moderador: Sergio Simon (SP) Tratamento Hormonal Extendido: por quanto tempo e para quem? Marcelo Cruz (SP) What is the ideal duration of Adjuvant Chemotherapy? Sara Hurvitz (USA) 12h45-14h30 14h30-16h00 16h00-16h30 16h30-17h15 Almoço/ Lunch Mesa Redonda: Situações Especiais Moderadores: Mastologista : Vilmar Marques de Oliveira (SP) Oncologista: Carlos A. Sampaio (BA) Tratamento do Câncer de Mama Inflamatório José Bines (RJ) Câncer de Mama em Homens: Sergio Roithmann (RS) Câncer de Mama Inicial abaixo dos 35 anos: Aspectos do Tratamento cirúrgico - Felipe Zerwes (RS) Aspectos do Tratamento Sistêmico - Max Mano (SP) Hot Topic I Moderador : Max Mano (SP) What is the best sequence for all the current alternatives in the treatment of HER2 positive disease? Sunil Verma (Canadá) 3

4 17h15-18h35 Mesa Redonda/Round Table - Tratamento Endócrino para a Doença Avançada/ Endocrine Therapy for advanced Disease Moderador: Carlos Barrios (RS) The PI3K/Akt/mTOR Pathway: What should the clinician know? Carlos Barrios (RS) Crosstalk between ER and PI3K/AKT/mTOR pathways: Resistance to Endocrine Therapy and Rational for Intervention - Cynthia Villarreal (México) PI3K/AKT/mTOR inhibitors in breast cancer: Current Clinical Evidence and Future perspectives? - Javier Cortes (Espanha) New alternatives for modulating endocrine therapy - Sara Hurvitz (USA) Dia 31 de agosto de 2013 SÁBADO 09h00-10h00 10h00-11h00 11h00 11h30 11h30 12h30 12h30-14h00 14h00 14h30 Mesa redonda/round Table - Tratamento local na Doença Inicial / Therapy in Early Disease Moderadores: Ivo Carelli (SP) e Paulo Roberto Pirozzi (SP) cn0: Do we need any supplementary axillary evaluation? Judy Boughey (USA) Nipple-sparing mastectomy without radiotherapy: What is the evidence? Antonio Frasson (RS) Radioterapia Parcial da Mama - Ernani Bronzatt (MG) Mesa Redonda/ Round Table - Hot Issues in Surgery Moderador: Carlos A. Ruiz (SP) Should BRCA carriers avoid breast conservative surgery? Judy Boughey (USA) Neoadjuvant treatment: Just to avoid mastectomy or whenever systemic adjuvant therapy is indicated? Kelly Hunt (USA) Controvérsia - Acompanhamento ativo é necessário? Moderador: Sérgio Roithmann (RS) Sim - Mario Alberto Costa (RJ) Não - Sergio Azevedo (RS) Almoço/Lunch O Que Podemos Esperar de Novo em Radioterapia Moderador: Fernando Obst ( RS) Radioterapia: O que está sendo estudado e quais os estudos em andamento que devemos lembrar? Rodrigo Hanriot (SP) 14h30-16h00 Hot topics II Moderadores: Mastologista: Guilherme Novita (SP) Oncologista: Carlos A. Sampaio ( BA) Neo-adjuvant Chemotherapy: a model for faster drug development? Javier Cortes (Espanha) The challenge of addressing resistance in HER2 positive disease - Sara Hurvitz (USA) 4

5 16h00-17h30 17h30 21h00 Mesa redonda - Tratamento da Doença Metastática Moderadores: Mastologista: Bárbara Pace (MG) Oncologista: Gustavo Ismael (SP) Manejo cirúrgico do tumor primário em pacientes com metástases à distância -João Henrique Penna Reis (MG) Contribuição dos taxanos no tratamento do câncer de mama Ricardo Caponero (SP) Algoritmo de tratamento do câncer de mama metastático em 2013 Antonio Buzaid (SP) Sumário e Conclusões Antonio Frasson (RS) e Carlos Barrios (RS) Jantar de Confraternização Local: Centro de Eventos do Hotel Serrano/ Espaço Érico Verissímo 5